Want to see HIND full AI Analyst Report?
HIND Stock Chart & Stats
$5.42
--
Market closed
$5.42
--
Day’s Range― - ―
52-Week Range$1.75 - $18.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)22.02K
Market Cap
$15.65M
Enterprise Value$3.50M
Total Cash (Recent Filing)$8.80M
Total Debt (Recent Filing)$22.55K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-38.80
Shares Outstanding7,018,528
10 Day Avg. Volume20,828
30 Day Avg. Volume22,020
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.04
Price to Sales (P/S)23.26
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue2.60
Enterprise Value/Gross Profit5.41
Enterprise Value/Ebitda-0.26
Forecast
1Y Price Target
$11.50Price Target Upside112.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityVery low reported leverage and positive equity in the most recent periods provide structural financial flexibility. This reduces bankruptcy risk, lowers interest burden, and gives management runway to execute strategy or raise capital under better terms than highly leveraged peers.
Healthy Gross MarginA near-50% gross margin indicates underlying product economics can support profitability if operating costs are reined in or revenue scales. Durable gross economics create optionality for margin recovery through cost discipline, pricing, or mix improvements over months to a few years.
Capital-structure Tightening And Governance SupportA large authorized-share reduction and shareholder ratification of leadership strengthen governance and reduce potential future dilution. Combined with board continuity, this structural move aligns capital structure with shareholder interests and can support long-term credibility with investors.
Bears Say
Sharp Revenue DeclineA nearly 45% TTM revenue drop signals structural demand or commercial execution problems. Sustained top-line deterioration undermines scale economics, makes fixed costs harder to cover, and lengthens the timeline to reach operating leverage necessary for durable profitability.
Persistent Negative Operating And Free Cash FlowMulti-year negative operating and free cash flow of several million dollars creates ongoing dependence on external financing. Chronic cash burn forces dilutive raises or financing at unfavorable terms, constraining investments in commercialization and R&D essential for long-term recovery.
Multi-year Losses And Negative Returns On EquityConsistent multi-year net losses and negative ROE indicate the company has not demonstrated ability to compound shareholder value. Without a clear path to sustained profitability, long-term capital allocation and strategic choices remain constrained and shareholder dilution risk rises.
Vyome Holdings News
HIND FAQ
What was Vyome Holdings, Inc.’s price range in the past 12 months?
Vyome Holdings, Inc. lowest stock price was $1.75 and its highest was $18.60 in the past 12 months.
What is Vyome Holdings, Inc.’s market cap?
Vyome Holdings, Inc.’s market cap is $15.65M.
When is Vyome Holdings, Inc.’s upcoming earnings report date?
Vyome Holdings, Inc.’s upcoming earnings report date is Nov 24, 2026 which is in 139 days.
How were Vyome Holdings, Inc.’s earnings last quarter?
Vyome Holdings, Inc. released its earnings results on May 28, 2026. The company reported -$0.15 earnings per share for the quarter, the consensus estimate of -$0.15 by $0.
Is Vyome Holdings, Inc. overvalued?
According to Wall Street analysts Vyome Holdings, Inc.’s price is currently Undervalued.
Does Vyome Holdings, Inc. pay dividends?
Vyome Holdings, Inc. does not currently pay dividends.
What is Vyome Holdings, Inc.’s EPS estimate?
Vyome Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vyome Holdings, Inc. have?
Vyome Holdings, Inc. has 7,018,528 shares outstanding.
What happened to Vyome Holdings, Inc.’s price movement after its last earnings report?
Vyome Holdings, Inc. reported an EPS of -$0.15 in its last earnings report, expectations of -$0.15. Following the earnings report the stock price went up 4.911%.
Which hedge fund is a major shareholder of Vyome Holdings, Inc.?
Currently, no hedge funds are holding shares in HIND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vyome Holdings, Inc.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
HIND Stock 12 Month Forecast
Average Price Target
$11.50
▲(112.18% Upside)
Technical Analysis
Ownership Overview
6.49% Insiders
0.36% Mutual Funds
― Other Institutional Investors
93.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---